Sociedad Americana de Hirudoterapia

Analysis of recombinant proteins by isoelectric focusing in immobilized pH gradients

Research article published in Electrophoresis (1992)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryFarmacología salivalDesarrollo de fármacosBischoff R et al. · Electrophoresis, 1992

Abstract

Isoelectric focusing in immobilized pH gradients (IEF-IPG) was used to analyze three different recombinant proteins. Recombinant leech hirudin (65 amino acids, three disulfide bonds) expressed in Saccharomyces cerevisiae as a secreted protein and purified by anion-exchange and reversed-phase chromatography proved to be homogeneous with regard to its isoelectric point (pI). In addition, the theoretical pI, calculated on the basis of the primary structure, corresponded precisely to the measured pI of 4.30. IEF-IPG was further employed to follow the stability of recombinant hirudin at pH 9, indicating that deamidation occurred under these conditions. A variant of recombinant human alpha 1-antitrypsin (AAT) (389 amino acids, one cysteine residue) expressed in Escherichia coli and purified by anion-exchange, metal chelate and hydrophobic-interaction chromatography appeared to be homogeneous by polyacrylamide gel electrophoresis under reducing and denaturing conditions as well as by various high performance liquid chromatography methods. However, some heterogeneity was detected by IEF-IPG between pH 5-6. The measured pI values of 5.43-5.58 were slightly lower than the calculated pI based on the primary structure (5.72). This indicated deamidations of Asn or Gln residues. A recombinant Schistosoma mansoni parasite antigen, p28 (210 amino acids, one cysteine residue) obtained after intracellular expression in Saccharomyces cerevisiae and affinity purification on glutathione agarose was analyzed by IEF-IPG in a pH 7.3-8.3 gradient. It appeared to be heterogeneous with regard to its pI, with the major component having a pI of 7.81 compared to the calculated value of 7.17.(ABSTRACT TRUNCATED AT 250 WORDS)

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAntigens, HelminthElectrophoresis, Polyacrylamide GelHelminth ProteinsHirudinsHydrogen-Ion ConcentrationImmunoblottingIsoelectric FocusingRecombinant ProteinsSoftwareVaccinesalpha 1-Antitrypsin

Resumen

IEF-IPG analysis of recombinant leech hirudin expressed in S. cerevisiae; homogeneous pI of 4.30 matching primary structure; deamidation detected under alkaline conditions.

Por qué esto importa para la hirudoterapia

This study used isoelectric focusing in immobilized pH gradients (IEF-IPG) to analyze three recombinant proteins, including recombinant leech hirudin expressed in Saccharomyces cerevisiae, assessing charge homogeneity and stability. Recombinant leech hirudin (65 amino acids, three disulfide bonds) proved homogeneous with a measured pI of 4.30 matching the theoretical value, while IEF-IPG also tracked deamidation at pH 9. For ASH, this work provides an analytical characterization of a leech-derived protein, though the abstract describes neither its biological function nor any pharmaceutical context. Caveat: This is an analytical methods paper focused on protein charge characterization; it contains no therapeutic, pharmacological, in vivo, or clinical data regarding hirudin's activity.

Citación

Analysis of recombinant proteins by isoelectric focusing in immobilized pH gradients.

Bischoff R et al. · Electrophoresis, 1992

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.